PATIENT AND CAREGIVER PREFERENCES FOR RAPID AND EARLY SEIZURE TERMINATION (REST): QUALITATIVE INTERVIEWS AND QUANTITATIVE SURVEY IN EUROPE
Author(s)
Kerrie-Anne Ho, PhD1, Tommi Tervonen, PhD2, Manuel Toledo Argany, MD, PhD3, Vicente Villanueva, MD, PhD4, Cecilia Jimenez Moreno, PhD5, Cedric Laloyaux, PhD6.
1UCB, Slough, United Kingdom, 2Kielo Research, Zug, Switzerland, 3Vall d'Hebron University Hospital, Barcelona, Spain, 4Universitario y Politecnico La Fe, Valencia, Spain, 5Kielo Research, York, United Kingdom, 6UCB, Brussels, Belgium.
1UCB, Slough, United Kingdom, 2Kielo Research, Zug, Switzerland, 3Vall d'Hebron University Hospital, Barcelona, Spain, 4Universitario y Politecnico La Fe, Valencia, Spain, 5Kielo Research, York, United Kingdom, 6UCB, Brussels, Belgium.
OBJECTIVES: Explore preferences of patients with epilepsy and caregivers for attributes of acute seizure medications for prolonged seizures (PS) in Europe, and perception of Rapid and Early Seizure Termination (REST) paradigm.
METHODS: Europe subgroup analysis of interview/survey of patients in France/Italy/Poland/Spain/UK/US (≥18 years) with ≥1 PS of >2 minutes in past 12 months and caregivers (≥18 years) of patients aged ≥12 years. The survey included a discrete choice experiment to elicit treatment preferences regarding mode of administration, treatment time window, time to stop the seizure, probability to stop the seizure within the timeframe, and no seizure recurrence for next 12 hours (analyzed using multinomial logit models). A willingness-to-wait exercise assessed preferences for timing of acute seizure medication administration.
RESULTS: In Europe, 44 patients/caregivers were interviewed; 57% (25/44) perceived REST approach as feasible, 27% (12/44) reported mode of administration would impact their decision to use acute medication; 41% (18/44) thought having a REST medication would reduce stress/provide peace of mind. 226 patients/caregivers participated in the survey; mean age 45.4 (SD 11.6) years, 66% (149/226) female. 56% (127/226) participants reported generalized/bilateral/tonic-clonic as most common seizure type; in past 12 months, 44% (99/226) reported average 3-5 seizures/month; 53% (119/226) reported average duration 1-4 minutes for most common seizure type. 57% (129/226) used oral medication for PS. All attributes significantly influenced treatment preferences (p<0.001); most important were time to stop the seizure (relative attribute importance [RAI]=31.2%, 95% CI=27.5, 34.6; fastest times preferred) and mode of administration (RAI=30.6%, 95% CI=26.3, 35.6; rectal administration least preferred). 85% (193/226) participants would not be willing to wait >30 seconds (minimum time proposed) to administer acute medication.
CONCLUSIONS: Patients with PS and caregivers in Europe prefer fast-acting acute seizure medications with non-rectal administration administered very early in the seizure. There is an unmet need to improve acute treatments for PS.
UCB-supported.
METHODS: Europe subgroup analysis of interview/survey of patients in France/Italy/Poland/Spain/UK/US (≥18 years) with ≥1 PS of >2 minutes in past 12 months and caregivers (≥18 years) of patients aged ≥12 years. The survey included a discrete choice experiment to elicit treatment preferences regarding mode of administration, treatment time window, time to stop the seizure, probability to stop the seizure within the timeframe, and no seizure recurrence for next 12 hours (analyzed using multinomial logit models). A willingness-to-wait exercise assessed preferences for timing of acute seizure medication administration.
RESULTS: In Europe, 44 patients/caregivers were interviewed; 57% (25/44) perceived REST approach as feasible, 27% (12/44) reported mode of administration would impact their decision to use acute medication; 41% (18/44) thought having a REST medication would reduce stress/provide peace of mind. 226 patients/caregivers participated in the survey; mean age 45.4 (SD 11.6) years, 66% (149/226) female. 56% (127/226) participants reported generalized/bilateral/tonic-clonic as most common seizure type; in past 12 months, 44% (99/226) reported average 3-5 seizures/month; 53% (119/226) reported average duration 1-4 minutes for most common seizure type. 57% (129/226) used oral medication for PS. All attributes significantly influenced treatment preferences (p<0.001); most important were time to stop the seizure (relative attribute importance [RAI]=31.2%, 95% CI=27.5, 34.6; fastest times preferred) and mode of administration (RAI=30.6%, 95% CI=26.3, 35.6; rectal administration least preferred). 85% (193/226) participants would not be willing to wait >30 seconds (minimum time proposed) to administer acute medication.
CONCLUSIONS: Patients with PS and caregivers in Europe prefer fast-acting acute seizure medications with non-rectal administration administered very early in the seizure. There is an unmet need to improve acute treatments for PS.
UCB-supported.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
PCR177
Topic
Patient-Centered Research
Disease
Neurological Disorders